Abstract
In the past decade, the strenuous efforts of the scientific community have substantially advanced our understanding of primary headaches. This research has promoted the development of novel disease-specific treatments, such as monoclonal antibodies and small molecules targeting the calcitonin gene-related peptide (CGRP) pathway, and agonists of the 5-HT1F receptor. However, despite these major advances, primary headaches still constitute a challenge for clinicians and a major burden for patients and society.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
